Showing 401-410 of 671 results for "".
- PatientFi Expands Co-marketing Agreement with Allerganhttps://practicaldermatology.com/news/patientfi-expands-co-marketing-agreement-with-allergan/2461148/PatientFi® is expanding its co-marketing agreement with Allergan Aesthetics, an AbbVie company, to provide financing options for patients interested in treatments such as BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM®Collection of Fillers, Natrelle® breast i
- Resilia Pharmaceuticals Obtains Marketing License for Solace Eczema Creamhttps://practicaldermatology.com/news/resilia-pharmaceuticals-obtains-marketing-license-for-solace-eczema-cream/2460967/Resilia Pharmaceuticals, Inc. will market and sell Solace™ Eczema Cream, a medical device, as an OTC product in the US, after signing a license agreement with Pelle Ventures, LLC. Financial terms of the transaction were not disclosed. Previously only avai
- Revlon Names Martine Williamson As Chief Marketing Officerhttps://practicaldermatology.com/news/revlon-names-martine-williamson-as-its-chief-marketing-officer/2460625/Martine Williamson is Revlon’s new Chief Marketing Officer. In this role, Williamson will be central to creating and spearheading global strategic plans across the brand portfolio and overseeing Revlon’s overall brand equity and architecture. Williamson officially join
- Marketing Exec Lizette Williams Joins RealSelf’s Boardhttps://practicaldermatology.com/news/lizette-williams-global-head-of-vertical-solutions-marketing-at-facebook-joins-realselfs-board/2460540/Marketing and advertising executive Lizette Williams is the newest member of RealSelf’s Board of Directors. Ms. Williams serves as the Global Head of Vertical Solutions Marketing at Facebook. Prior to Facebook she has worked in major marketing roles at McDonald's, Kimberl
- Suneva to Market and Distribute Neauvia's Plasma IQ in North Americahttps://practicaldermatology.com/news/suneva-to-market-and-distribute-neauvias-plasma-iq-in-north-america/2460534/Suneva Medical, Inc., will market and distribute Neauvia Plasma IQ throughout North America as part of a new partnership. The first Class 2 FDA-cleared plasma energy device, Plasma IQ delivers focused, controlled plasma energy to create microinjuries on the skin, renewing
- SENTÉ Names Adelle Walker as Chief Marketing Officerhttps://practicaldermatology.com/news/sente-names-adelle-walker-as-chief-marketing-officer/2460080/SENTÉ® has appointed Adelle Walker Chief Marketing Officer. As Chief Marketing Officer (CMO), she will take an executive leadership role in defining pipeline strategy along with internal and external portfolio planning. Her commercialization leadership will span across all fa
- ISHRS Awareness Campaign Takes on Black Market Hair Restoration Clinicshttps://practicaldermatology.com/news/ishrs-awareness-campaign-takes-on-black-market-hair-restoration-clinics/2460016/The International Society of Hair Restoration Surgery (ISHRS) is launching a new public awareness campaign to help patients recognize “black market pirate” hair restoration clinics and misleading advertising claims. Social media engagement will be the cornerstone of the new
- Encore Dermatology Acquires Marketing Rights to Promius Pharma Brandshttps://practicaldermatology.com/news/encore-dermatology-acquires-marketing-rights-to-promius-pharma-brands-1/2459989/Encore Dermatology is purchasing the US rights to market Sernivo® (betamethasone dipropionate) Spray, 0.05% and is being assigned the rights to market and distribute Promiseb® Topical Cream and Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) from Dr. Reddy’
- Dermatology Drugs Market to Reach $34.5 Billion by 2023https://practicaldermatology.com/news/dermatology-drugs-market-to-reach-345-billion-by-2023/2459895/The dermatology drugs market is expected to reach $34.5 billion by 2023, a new report suggests. Research and Markets says that, among
- Almirall's Seysara Set to Shake Up US Acne Markethttps://practicaldermatology.com/news/almiralls-seysara-set-to-shake-up-us-acne-market/2457557/The US Food and Drug Administration’s approval of Almirall’s Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older is set to shake up the currently stagnant acne market due to its ease of adminis